Additionally, the 36-month beta value for IMMP is 1.77. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMMP is 144.81M and currently, short sellers hold a 2.86% ratio of that float. The average trading volume of IMMP on June 13, 2025 was 275.96K shares.
IMMP) stock’s latest price update
The stock of Immutep Limited ADR (NASDAQ: IMMP) has decreased by -6.49 when compared to last closing price of 1.85.Despite this, the company has seen a loss of -2.81% in its stock price over the last five trading days. globenewswire.com reported 2025-05-27 that SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. The novel combination significantly exceeded the study’s prespecified median of 35% tumour hyalinization/fibrosis versus 15% for historical data from radiotherapy alone in patients with resectable soft tissue sarcoma (STS).
IMMP’s Market Performance
IMMP’s stock has fallen by -2.81% in the past week, with a monthly drop of -8.47% and a quarterly drop of -1.14%. The volatility ratio for the week is 3.39% while the volatility levels for the last 30 days are 3.29% for Immutep Limited ADR The simple moving average for the past 20 days is -9.27% for IMMP’s stock, with a -12.30% simple moving average for the past 200 days.
Analysts’ Opinion of IMMP
Many brokerage firms have already submitted their reports for IMMP stocks, with CapitalOne repeating the rating for IMMP by listing it as a “Overweight.” The predicted price for IMMP in the upcoming period, according to CapitalOne is $10 based on the research report published on May 17, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see IMMP reach a price target of $7. The rating they have provided for IMMP stocks is “Outperform” according to the report published on August 03rd, 2023.
Ladenburg Thalmann gave a rating of “Buy” to IMMP, setting the target price at $8.30 in the report published on August 03rd of the previous year.
IMMP Trading at -2.08% from the 50-Day Moving Average
After a stumble in the market that brought IMMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.21% of loss for the given period.
Stock Fundamentals for IMMP
Current profitability levels for the company are sitting at:
- -12.82 for the present operating margin
- 0.41 for the gross margin
The net margin for Immutep Limited ADR stands at -11.38. The total capital return value is set at -0.33. Equity return is now at value -31.16, with -29.32 for asset returns.
Based on Immutep Limited ADR (IMMP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -29.21. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -2202.69.
Currently, EBITDA for the company is -44.54 million with net debt to EBITDA at 2.85. When we switch over and look at the enterprise to sales, we see a ratio of 72.21. The receivables turnover for the company is 0.44for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.86.
Conclusion
In conclusion, Immutep Limited ADR (IMMP) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
